William C JR Bertrand
CIK 1291937 · Chief Operating Officer · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.27M
Companies
6
Total Filings
50
Lifetime Open-Market Net
$43.8K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARDX | Director | 329,507 | $4.00 | $1.32M | $100.0K | 14 | 2026-06-18 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Chief Operating Officer | 986,352 | $0.06 | $57.1K | -$44.0K | 23 | 2025-08-29 |
| ASND | Chief Operating Officer | 3,731 | $255.41 | $952.9K | -$12.2K | 3 | 2019-01-16 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | General Counsel | — | $0.04 | — | $0 | 1 | 2015-10-21 |
| SALIX PHARMACEUTICALS LTD (SLXP) Delisted | See Remarks | 31,258 | — | — | $0 | 2 | 2015-02-03 |
| MEDI | SVP, General Counsel, Sec | 0 | $33.99 | $0 | $0 | 3 | 2007-06-19 |
Recent Filings · Page 2 of 5
50 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −23,589 | -$16.4K | EDGAR |
| 2024-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-12 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −9,229 | -$7.8K | EDGAR |
| 2023-06-16 | ARDX | Grant (A) | +16,581 | $0 | EDGAR |
| 2023-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −4,440 | -$8.2K | EDGAR |
| 2023-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-12 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −8,816 | -$15.2K | EDGAR |
| 2023-01-04 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −3,584 | -$6.1K | EDGAR |
| 2022-06-17 | ARDX | Grant (A) | +118,613 | $0 | EDGAR |
| 2022-01-18 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −4,368 | -$13.9K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.